FDA Approves Daunorubicin + Cytarabine for Secondary Acute Myeloid Leukemia

On March 30, 2021, the U.S. Food and Drug Administration approved the revised label for daunorubicin and cytarabine to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes in pediatric patients aged one year and older.

Read the Jazz Pharmaceuticals announcement.

Posted 3/31/2021